Biosolvix, a company in animal alternative testing, has signed a memorandum of understanding with the Innovative Institute for Precision Medicine
at Research Institute for Future Medicine Samsung Medical Center (led by Director Cho Yong-beom) for the development of tumor organoid technology.
This agreement aims to foster collaboration between the two parties to contribute to the advancement of the domestic animal alternative testing industry and
the development of personalized medicines for patients.
Biosolvix and Samsung Medical Center will share research infrastructure and technical expertise for the development of tumor organoid co-culture technology.
We plan to conduct research on new animal replacement testing methods and the selection of personalized medicines for patients.
Choi Soo-young, CEO of Biosolvix, stated, "This agreement with Samsung Medical Center marks the significant beginning of our main focus on the cancer organoid business.
Building on this agreement, we will continue collaboration through technology transfer, joint research, and future partnerships with various institutions to achieve stable revenue generation in the near future."